首页> 外文期刊>The Journal of Urology >Prostate cancer detection at low prostate specific antigen.
【24h】

Prostate cancer detection at low prostate specific antigen.

机译:前列腺特异性抗原低的前列腺癌检测。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: At low prostate specific antigen (PSA) the indication for prostate biopsy is usually an abnormal digital rectal examination. We evaluate the diagnostic value of PSA, digital rectal examination, transrectal ultrasonography and tumor characteristics at low PSA (0 to 4.0 ng./ml.). We confirm and add to recent evidence that digital rectal examination has a low predictive value and that many significant cancers at this PSA range may be missed. MATERIALS AND METHODS: From 1994 to 1997 a total of 10,523 participants 54 to 74 years old were randomized to screening in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Of the participants 9,211 (87.5%) had PSA less than 4.0 ng./ml., and underwent digital rectal examination and transrectal ultrasonography. Expected rates of prostate cancer detection were calculated using logistic regression analysis. Radical prostatectomy was performed in about half of the 478 men diagnosed with prostate cancer. Tumors were characterized by pT category, Gleason score and cancer volume in 166 processed radical prostatectomy specimens. In 50 of these cases PSA was 0 to 4.0 ng./ml. RESULTS: The positive predictive value of digital rectal examination and transrectal ultrasonography at PSA 0 to 4.0 ng./ml. was only 9.7%. Positive predictive value strongly depended on PSA. Sensitivity was calculated by using estimates of the prevalence of sextant biopsy detectable prostate cancers. Of 760 detectable cancers 478 (67%) were diagnosed irrespective of PSA in men screened with digital rectal examination, transrectal ultrasonography and PSA. Only 127 of 348 detectable prostate cancers (36.5%) were actually diagnosed in men with PSA 2 to 4 mg./ml. The importance of these missed cancers was evaluated with parameters of tumor aggressiveness within PSA ranges. CONCLUSIONS: Approximately half of the tumors missed with PSA 0 to 4 ng./ml. had aggressive characteristics (Gleason score 7 or greater, Gleason 4-5 components) and were organ confined. These tumors should be diagnosed and treated according to the present understanding of their natural history. More sensitive and selective screening strategies are needed. Presently a wrong "window of opportunity" is used for early detection of prostate cancer.
机译:目的:在前列腺特异性抗原(PSA)低的情况下,前列腺穿刺活检的指征通常是直肠指检异常。我们评估低PSA(0至4.0 ng./ml。)时PSA的诊断价值,直肠指检,经直肠超声检查和肿瘤特征。我们确认并补充了最近的证据,即直肠指检的预测价值较低,并且可能会错过该PSA范围内的许多重要癌症。材料与方法:从1994年至1997年,共有54到74岁的10,523名参与者被随机分配到欧洲前列腺癌筛查随机研究的鹿特丹部分。在参与者中,有9,211名(87.5%)的PSA低于4.0 ng./ml,并接受了直肠指检和经直肠超声检查。使用logistic回归分析计算了预期的前列腺癌检出率。在诊断为前列腺癌的478名男性中,约有一半进行了前列腺根治术。在166例经手术的前列腺癌根治术标本中,通过pT类别,格里森评分和癌症体积来表征肿瘤。在其中50例中,PSA为0至4.0 ng./ml。结果:PSA 0至4.0 ng./ml时,直肠指检和经直肠超声检查对阳性预测价值较高。只有9.7%。阳性预测值在很大程度上取决于PSA。通过使用六分点活检可检出的前列腺癌患病率的估计值来计算敏感性。在通过数字直肠检查,经直肠超声检查和PSA筛查的男性中,无论是否患有PSA,在760种可检测到的癌症中,有478例(67%)被诊断出。 348例PSA为2至4 mg./ml的男性实际上仅诊断出127种可检测的前列腺癌(36.5%)。这些遗漏的癌症的重要性通过PSA范围内的肿瘤侵袭性参数进行了评估。结论:PSA 0至4 ng./ml约有一半的肿瘤漏诊。具有侵略性特征(格里森得分7或更高,格里森4-5个组成部分),并局限于器官内。这些肿瘤应根据目前对其自然病史的理解进行诊断和治疗。需要更敏感和选择性的筛选策略。目前,错误的“机会之窗”被用于早期检测前列腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号